Access the full text.
Sign up today, get DeepDyve free for 14 days.
I. Kushner, Shun Jiang, Dongxiao Zhang, G. Lozanski, D. Samols (1995)
Do Post‐transcriptional Mechanisms Participate in Induction of C‐reactive Protein and Serum Amyloid A by IL‐6 and IL‐I? aAnnals of the New York Academy of Sciences, 762
(2000)
Interleukin - 6 is associated with insulin resistance independently of obesity
D. Torpy, D. Papanicolaou, A. Lotsikas, R. Wilder, G. Chrousos, S. Pillemer (2000)
Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia.Arthritis and rheumatism, 43 4
J. Fernández-Real, W. Ricart (1999)
Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftinessDiabetologia, 42
D. Papanicolaou, J. Petrides, C. Tsigos, S. Bina, K. Kalogeras, R. Wilder, P. Gold, P. Deuster, G. Chrousos (1996)
Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines.The American journal of physiology, 271 3 Pt 1
The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Hormone Replacement Therapy and Interrelation between Serum Interleukin-6 and Body Mass Index in Postmenopausal Women: A Population-Based Study
Pickup (1997)
NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.Diabetologia, 40
A. Vgontzas, D. Papanicolaou, E. Bixler, A. Kales, K. Tyson, G. Chrousos (1997)
Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity.The Journal of clinical endocrinology and metabolism, 82 5
Z. Orban, A. Remaley, M. Sampson, Z. Trajanoski, G. Chrousos (1999)
The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man.The Journal of clinical endocrinology and metabolism, 84 6
(1997)
Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression of Somatostatin Receptor SST4 in Human Placenta and Absence of Octreotide Effect on Human Placental Growth Hormone Concentration during
Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo*
S. Sandler, K. Bendtzen, D. Eizirik, M. Welsh (1990)
Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro.Endocrinology, 126 2
S. Pottratz, T. Bellido, H. Mocharla, David, Crabb, S. Manolagas (1994)
17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism.The Journal of clinical investigation, 93 3
J. Stouthard, J. Romijn, T. Poll, E. Endert, S. Klein, P. Bakker, C. Veenhof, H. Sauerwein (1995)
Endocrinologic and metabolic effects of interleukin-6 in humans.The American journal of physiology, 268 5 Pt 1
Tamara Harris, L. Ferrucci, R. Tracy, M. Corti, S. Wacholder, W. Ettinger, Harley Heimovitz, H. Cohen, R. Wallace (1999)
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.The American journal of medicine, 106 5
Fried (1998)
Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid.J Clin Endocrinol Metab, 83
D. Papanicolaou, R. Wilder, S. Manolagas, G. Chrousos (1998)
The Pathophysiologic Roles of Interleukin-6 in Human DiseaseAnnals of Internal Medicine, 128
J. Yudkin, M. Kumari, S. Humphries, V. Mohamed-ali (2000)
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?Atherosclerosis, 148 2
A. Vgontzas, D. Papanicolaou, E. Bixler, Kenneth Hopper, A. Lotsikas, Huong-Mo Lin, A. Kales, G. Chrousos (2000)
Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.The Journal of clinical endocrinology and metabolism, 85 3
T. Jones (1994)
Interleukin‐6 an endocrine cytokineClinical Endocrinology, 40
D. Papanicolaou (2000)
Interleukin-6: the endocrine cytokine.The Journal of Clinical Endocrinology and Metabolism, 85
Straub (2000)
Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study.J Clin Endocrinol Metab, 85
C. Tsigos, D. Papanicolaou, I. Kyrou, Ruby Defensor, C. Mitsiadis, G. Chrousos (1997)
Dose-dependent effects of recombinant human interleukin-6 on glucose regulation.The Journal of clinical endocrinology and metabolism, 82 12
J. Fernández-Real, M. Broch, Joan Vendrell, C. Gutiérrez, R. Casamitjana, M. Pugeat, C. Richart, W. Ricart (2000)
Interleukin-6 gene polymorphism and insulin sensitivity.Diabetes, 49 3
A. Szalai, F. Ginkel, S. Dalrymple, R. Murray, J. Mcghee, J. Volanakis (1998)
Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice.Journal of immunology, 160 11
S. Campos, Heinz, '. Baumann (1992)
Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genesMolecular and Cellular Biology, 12
C. Southern, D. Schulster, D. Schulster, Irene Green (1990)
Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. An effect distinct from that of interleukin-1.The Biochemical journal, 272 1
M. Visser, L. Bouter, G. Mcquillan, M. Wener, T. Harris (1999)
Elevated C-reactive protein levels in overweight and obese adults.JAMA, 282 22
S. Kado, Terumasa Nagase, N. Nagata (1999)
Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitusActa Diabetologica, 36
2000 Interleukin 6 and insulin sensitivity . Diabetes
Walter Gonzalez, V. Fontaine, M. Pueyo, Nathalie Laquay, David Messika-Zeitoun, Monique Philippe, J. Arnal, Marie-Paule Jacob, J. Michel (2000)
Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals.Hypertension, 36 1
T. Makino, Y. Noguchi, Takaki Yoshikawa, C. Doi, K. Nomura (1998)
Circulating interleukin 6 concentrations and insulin resistance in patients with cancerBritish Journal of Surgery, 85
H. Besedovsky, A. Rey (1996)
Immune-neuro-endocrine interactions: facts and hypotheses.Endocrine reviews, 17 1
P. Tappia, Kerry Troughton, S. Langley-Evans, R. Grimble (1995)
Cigarette smoking influences cytokine production and antioxidant defences.Clinical science, 88 4
J. Pickup, M. Crook (1998)
Is Type II diabetes mellitus a disease of the innate immune system?Diabetologia, 41
Mohamed-Ali (1997)
Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo.J Clin Endocrinol Metab, 82
J. Bastard, C. Jardel, E. Bruckert, P. Blondy, J. Capeau, M. Laville, H. Vidal, B. Hainque (2000)
Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.The Journal of clinical endocrinology and metabolism, 85 9
H. Yki-Järvinen, K. Sammalkorpi, V. Koivisto, E. Nikkilä (1989)
Severity, duration, and mechanisms of insulin resistance during acute infections.The Journal of clinical endocrinology and metabolism, 69 2
Masaharu Morohoshi, Kazuhiko Fujisawa, Isao Uchimuraa, F. Numano (1996)
Glucose-Dependent Interleukin 6 and Tumor Necrosis Factor Production by Human Peripheral Blood Monocytes In VitroDiabetes, 45
There is increasing evidence that systemic inflammation and insulin resistance constitute interrelated events that contribute to atherosclerosis. We studied the effect of the association between circulating interleukin 6 (IL-6) levels, one of the major mediators of inflammation, and C-reactive protein on insulin resistance and blood pressure in 228 healthy volunteers.The plasma IL-6 concentration was significantly and similarly associated with systolic (SBP) and diastolic (DBP) blood pressure, fasting insulin, and the fasting insulin resistance index (FIRI) in all subjects. When smokers were excluded from the analysis, plasma IL-6 levels correlated with percent fat mass (r = 0.19; P = 0.02), absolute fat mass (r = 0.17; P = 0.03), SBP, DBP, fasting insulin levels, and FIRI. The latter associations persisted after controlling for body mass index (r = 0.15 and r = 0.19; P = 0.02 and P = 0.0004 for SBP and DBP, respectively; r = 0.24 and r = 0.19, P = 0.004 and P = 0.03, for fasting insulin and FIRI, respectively).Gender and smoking status significantly influenced the results. Although IL-6 levels were significantly associated with fasting insulin and FIRI in men, these significant correlations were not observed in women. Conversely, although IL-6 levels were significantly associated with SBP and DBP in women, these coefficients were not statistically significant in men. All of these associations were lost among smokers and remained significant in nonsmokers.As IL-6 is the major mediator of the acute phase response by hepatocytes and induces the synthesis of C-reactive protein (CRP), we also controlled for the latter. Serum CRP levels correlated significantly with IL-6 in all the subjects, but mainly in nonsmokers and men. Of note was that this significant relationship was lost among smokers. CRP was associated with fasting insulin (r = 0.28; P < 0.0001) and FIRI (r = 0.25; P < 0.0001), but not with SBP or DBP (P = NS), in all subjects. Unlike IL-6, the associations between CRP and these parameters were similar in men and women and in smokers and nonsmokers. For insulin and FIRI they were stronger in women and in nonsmokers. CPR significantly correlated with the WHR only in men (r = 0.22; P = 0.01).Using multiple linear regression in a stepwise manner to predict circulating IL-6 levels, smoking status (P = 0.0059) and FIRI (P = 0.03), but not fat mass or SBP, independently contributed to 11% of its variance in men. When CRP was introduced into the model, the latter (P < 0.0001) and smoking status (P = 0.02), but not FIRI, fat mass, or SBP, contributed to 33% of the variance in IL-6 levels. In women, only SBP (P = 0.04) contributed to 5% of its variance. When CRP was introduced into the model, again only SBP (P = 0.01) contributed to 10% of the variance in IL-6 levels.In 25 of these subjects, insulin sensitivity was determined using the frequently sampled iv glucose tolerance test with minimal model analysis, and circulating IL-6 levels were strongly associated with the insulin sensitivity index (r = −0.65; P < 0.0001). Again, this relationship was even stronger in men (r =− 0.75; P < 0.001) and was not significant in women (r = −0.26; P = NS). In all of these subjects, only insulin sensitivity (P = 0.0037), not fat mass, contributed to 21% of the variance of IL-6 levels in a multiple linear regression analysis.In summary, circulating IL-6 levels, by inducing either hypertension in women or insulin resistance in men, constitute a significant proatherogenic cytokine. The mechanisms of these associations should be further investigated.
Journal of Clinical Endocrinology and Metabolism – Oxford University Press
Published: Mar 1, 2001
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.